Veterinary Medicine Advances: NOBIVAC NXT Vaccine for Feline Leukemia Virus
Overview of the NOBIVAC NXT FeLV Vaccine
Merck Animal Health has announced the expansion of its NOBIVAC NXT vaccination platform to include a solution against feline leukemia virus (FeLV), which is one of the most prevalent infectious diseases in felines. The NOBIVAC NXT FeLV is offered as a low-volume 0.5 mL dose, which is nonadjuvanted, maintaining comfort and safety during vaccination.
Vaccine Administration and Effectiveness
The NOBIVAC NXT FeLV is intended for cats 8 weeks or older and will be available nationwide in fall 2024. This vaccine is particularly noteworthy as it is built on Merck's innovative RNA-particle technology. Administered in two doses, spaced three to four weeks apart, this vaccine has a proven duration of immunity for two years.
Importance of Vaccination Against FeLV
Feline leukemia virus poses significant health risks for cats, being a retrovirus that can integrate into a cat's genome, which complicates treatment. The virus spreads through mutual grooming, fighting, and sharing resources. Cats exhibiting FeLV symptoms may develop severe health issues, including cancer and blood disorders. Hence, vaccination is crucial, especially for kittens with immature immune systems.
Statement from Merck Animal Health
“We are proud to extend our RNA-particle technology with a vaccine that protects against one of the most persistent threats to our feline patients,” stated Ian Tarpey, PhD, Vice President of Research and Development at Merck Animal Health. Dr. Meg Conlon, DVM, emphasized the importance of raising awareness about the necessity of vaccinations for feline health.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.